Roivant Sciences (ROIV) AI Stock Analysis

• Market Cap: $7.38B
• Dividend Yield: N/A
• Average Volume (3M): 6.76M
• Price to Earnings (P/E): 1.9
• Beta (1Y): 0.97
• Revenue Growth: -38.94%
• EPS Growth: -104.46%
• Country: US
• Employees: 908
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 679,806,100
• 10 Day Avg. Volume: 7,219,746
• 30 Day Avg. Volume: 6,756,342
• PEG Ratio: 0.66
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.22
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 11.29
• Enterprise Value/Gross Profit: 73.69
• Enterprise Value/Ebitda: 0.39
• 1Y Price Target: $15.10
• Price Target Upside: 34.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 54 Neutral
• Price Target: $11.50 ▲(2.50%Upside)

Roivant Sciences' overall score reflects significant financial challenges and valuation concerns, partially offset by a strong cash position and promising pipeline developments. Corporate initiatives, such as share repurchases and leadership changes, also contribute positively. However, competition and litigation pose notable risks.

Positive Factors

Clinical Trials

The topline data from the Phase 3 VALOR study of brepocitinib in dermatomyositis is the next key catalyst for Roivant and could meaningfully expand the opportunity for the drug.

Drug Differentiation

Brepocitinib is highly differentiated in its convenient oral dosing and novel mechanism-of-action, with potential to become the first approved JAK inhibitor in the dermatomyositis space.

Stock Repurchase

ROIV disclosed that it had repurchased $205M in stock and announced a new authorization for the repurchase of up to $500M in stock.

Negative Factors

Placebo Response Concerns

Investors may be overly concerned about the placebo response in the forthcoming Ph3 brepocitinib dermatomyositis trial results, and there are signals that JAK inhibitors benefit muscle.

Regulatory Challenges

ROIV has not asked FDA for fast track nor breakthrough therapy designation in dermatomyositis because it doesn’t have the data to justify doing so.

Roivant Sciences Business Overview & Revenue Model

Company Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

How the Company Makes Money

Roivant Sciences makes money primarily through the development and commercialization of pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials and obtaining regulatory approval for their sale. Roivant may also earn income through licensing agreements, partnerships, and collaborations with other pharmaceutical companies, where they might receive upfront payments, milestone-based payments, and royalties on sales. Additionally, Roivant's unique business model of creating Vants allows for the potential monetization of these subsidiaries through mergers, acquisitions, or public offerings, contributing further to their financial growth.

Roivant Sciences Financial Statement Overview

Summary

Roivant Sciences faces financial challenges, including declining revenues, consistent losses, and negative cash flows. Despite a strong equity position, profitability and cash generation are under pressure, raising concerns about long-term viability.

Income Statement

Roivant Sciences shows significant volatility in revenue with a declining trend from 2020 to 2025. The company has faced substantial EBIT and net income losses consistently, indicating operational challenges. Gross Profit Margin has been positive, but high EBIT and EBITDA losses reflect underlying inefficiencies.

Balance Sheet

The company's balance sheet highlights a strong equity position relative to debt, with total debt significantly lower than equity. However, the company's continuous negative net income impacts return on equity. The equity ratio is high, suggesting financial stability, but the persistent losses pose a risk.

Cash Flow

Roivant Sciences demonstrates weak cash flow management with consistently negative operating and free cash flows. Although investments have been substantial, operational cash flow remains negative, and free cash flow shows no growth, indicating challenges in converting revenue into cash.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	29.05M	124.80M	61.28M	55.29M	23.80M
Gross Profit	28.14M	96.83M	48.15M	46.32M	21.74M
EBITDA	-1.10B	4.31B	-1.18B	-916.71M	-895.74M
Net Income	-171.98M	4.35B	-1.01B	-845.26M	-809.23M
Balance Sheet
Total Assets	5.44B	7.22B	2.39B	2.59B	2.69B
Cash, Cash Equivalents and Short-Term Investments	4.89B	6.54B	1.68B	2.06B	2.13B
Total Debt	100.17M	499.75M	481.40M	283.89M	244.98M
Total Liabilities	249.74M	773.95M	782.02M	523.70M	527.69M
Stockholders Equity	4.69B	5.97B	1.16B	1.66B	1.80B
Cash Flow
Free Cash Flow	-844.05M	-766.65M	-856.08M	-695.16M	-557.94M
Operating Cash Flow	-839.45M	-765.27M	-843.39M	-677.73M	-552.14M
Investing Cash Flow	-1.77B	5.20B	-44.27M	303.30M	-31.70M
Financing Cash Flow	-1.22B	419.36M	499.46M	306.79M	456.26M

Roivant Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Positive. The current price of 11.22 is below the 20-day moving average (MA) of 11.26, above the 50-day MA of 11.15, and above the 200-day MA of 11.18, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 58.70 is Neutral, neither overbought nor oversold. The STOCH value of 57.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROIV.

Roivant Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	78 Outperform	$6.97B	15.29	147.06%	―	25.65%	57.10%
JAZZ	75 Outperform	$6.60B	15.05	12.25%	―	5.76%	49.58%
BBIO	60 Neutral	$8.73B	―	35.68%	―	-41.71%	-9.37%
LEGN	60 Neutral	$6.90B	―	-20.00%	―	112.46%	54.33%
MDGL	56 Neutral	$6.38B	―	-50.16%	―	―	21.83%
ROIV	54 Neutral	$7.38B	1.93	-8.56%	―	-38.94%	-104.46%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%

Roivant Sciences Corporate Events

Roivant Sciences Announces $500M Share Repurchase Program

Roivant Sciences Ltd. has announced a new common share repurchase program on June 24, 2025, allowing for the repurchase of up to $500 million of its common shares. This initiative follows a previous $1.5 billion repurchase program from April 2024, which has been fully utilized. The repurchase will be funded with available cash, with no set expiration date, and will depend on market conditions and other factors.

The most recent analyst rating on (ROIV) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Roivant Sciences Announces Leadership Changes at Immunovant

On April 21, 2025, Roivant Sciences announced significant leadership changes at its subsidiary, Immunovant, Inc., including the appointment of Eric Venker as CEO and Tiago Girao as CFO, as part of a strategic transition to enhance operational involvement and oversight. The company is expanding the development of its drug IMVT-1402 into two new indications, Sjögren’s Disease and Cutaneous Lupus Erythematosus, with promising clinical data and a strong cash position to support these initiatives, potentially impacting its market positioning and stakeholder interests.